Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive ChemotherapyMarta Libura, W Wiktor-Jędrzejczak, Elżbieta Patkowska et al.|Cancers|2023Cited by 3
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2025Cited by 1
Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell TransplantationAnna Czyż, Agnieszka Wierzbowska, Małgorzata Sobczyk‐Kruszelnicka et al.|Blood|2022Cited by 0
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)Agnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2022Cited by 0
Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2022Cited by 0